Cell cycle regulation, apoptosis, oxidative stress and inflammation response play critical roles in the development of smokinginduced lung cancer. However, it is still not well known whether their genetic variants are associated with lung cancer susceptibility. In this study, we performed imputation-based association analyses to investigate the influence of common genetic variants in these pathways and their interactions with smoking on lung cancer susceptibility. We first selected 24 042 unvalidated genetic variants in 798 genes from the imputed dataset of the previous lung cancer genome-wide association study in 2331 cases and 3077 controls, and then conducted additional two-stage validations in 4133 cases and 4522 controls. We found a genome-wide significant (P < 5.0 × 10 -8 ) association for rs2282987 in CDK6 at 7q21.2 [odds ratio (OR) = 1.18, combined P add = 2.27 × 10
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Introduction
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths worldwide (1) . A deep insight into the genetic basis underlying lung cancer development is strongly needed to elucidate the lung cancer etiology and identify the high-risk populations for surveillance and prevention. Recent genome-wide association studies (GWAS) in Chinese populations have identified multiple lung cancer susceptibility loci (2, 3) . However, most identified loci have small effects [odds ratio (OR) of 1.3 or smaller] and thus only explain a fraction of lung cancer susceptibility variation, suggesting that additional lung cancer susceptibility loci remain to be explored. Genotype imputation is a powerful statistical tool for making predictions of the ungenotyped 'hidden' variations, and imputation-based association analyses can facilitate us to further discover the novel associations (4) (5) (6) (7) .
In addition, there is accumulating evidence that genetic factors may interact with environmental factors to contribute to lung cancer susceptibility (8, 9) . Smoking is the most crucial environmental risk factor in lung cancer etiology. It is estimated that smoking accounts for ~80% of global lung cancer burden in males and 50% in females (1) . Cigarette smoke is a complex mixture of numerous carcinogens and oxidants, which can induce multiple important cancer-related changes, such as cell cycle dysregulation (10, 11) , abnormal apoptosis (12) , oxidative stress (13) and inflammation response (14, 15) , and further induce abnormal cell proliferation and death, oxidative DNA damages and cancer-promoting inflammatory microenvironments, eventually leading to lung cancer (16) (17) (18) (19) (20) . Genetic variants involved in pathways of cell cycle regulation, apoptosis, oxidative stress and inflammation response and their interactions with smoking may contribute to interindividual variation in regulating these cancer-related changes and may eventually influence lung cancer susceptibility. To date, a few studies have explored genetic variants in these pathways in relation to lung cancer susceptibility (21) (22) (23) (24) , but the associations are limited to a small sample size and a few tag single nucleotide polymorphisms (SNPs), and there is a need to evaluate a wider range of SNPs in these pathways and their interactions with smoking in large Chinese populations. Therefore, with the aim to investigate the influence of common genetic variants in the pathways of cell cycle regulation, apoptosis, oxidative stress and inflammation response and their interactions with smoking on lung cancer susceptibility in Chinese populations, we took imputation-based association analyses to screen 24 042 common SNPs of 798 genes in these pathways from the imputed dataset of a previous lung cancer GWAS in 2331 cases and 3077 controls (2, 3) , and then conducted additional two-stage validations in a total of 4133 cases and 4522 controls.
Materials and methods

Study subjects
We performed a three-stage case-control study with a total of 6464 lung cancer cases and 7599 controls. All these cases and controls were unrelated ethnic Han Chinese as reported previously (2, 3, (25) (26) (27) (28) . The distributions of selected characteristics for subjects in our study were summarized in Supplementary  Table S1 , available at Carcinogenesis Online. The study population of the initial GWAS consisted of 2331 cases and 3077 controls from two studies (Nanjing GWAS study: 1473 cases and 1962 controls; Beijing GWAS study: 858 cases and 1115 controls) (2, 3) . The first-stage validation (validation I) consisted of 2304 cases and 2688 controls (1862 cases and 2688 controls from Wuhan, and 442 cases from Beijing) (25) (26) (27) . The second-stage validation (validation II) consisted of 1829 cases and 1834 controls from Guangzhou (28) . The lung cancer cases were histopathologically or cytologically confirmed by at least two local pathologists. The cancer-free controls were selected from those receiving routine physical examinations or participating in the community New variants, interactions and lung cancer risk screening of non-communicable diseases and frequency matched to each set of the cases in terms of age and gender. The detailed smoking information was collected through interviews. Individuals who had smoked <1 cigarette per day and <1 year in their lifetime were defined as non-smokers; otherwise, they were considered as smokers. As 27 pack-years was the median pack-years in the smokers of our combined controls, we classified smokers who had ≤27 pack-years history of smoking as light smokers and smokers who had >27 pack-years history of smoking as heavy smokers. All participants provided written informed consent, and this study was approved by the institutional review boards of each participating institution.
GWAS and genotype imputation
The GWAS was conducted with Affymetrix Genome-Wide Human SNP Array 6.0. After a stringent quality control that had been described in detail previously (2,3), 2331 lung cancer cases and 3077 controls with 591 370 SNPs were finally included in the genotype imputation. Genotype imputation was conducted by the MACH 1.0 software (http://www.sph.umich.edu/csg/abecasis/ MACH/index.html) with the linkage disequilibrium (LD) information from the HapMap phase II database (Han Chinese in Beijing and Japanese in Tokyo as the reference set, released 17 July 2006) (2) . Imputed SNPs with low imputation quality (r 2 < 0.3) were excluded from further consideration.
Genes and SNPs selection and genotyping
We compiled the list of genes involved in cell cycle regulation, apoptosis, oxidative stress and inflammation response in a broad sense, i. Table S2 , available at Carcinogenesis Online). SNPs for validation I were selected to fit the following criteria: (i) P add ≤ 1.0 × 10 -4 in the imputed GWAS dataset, (ii) call rate ≥ 90% in all GWAS samples and in both the Nanjing Study and the Beijing Study, (iii) Hardy-Weinberg equilibrium P value in controls ≥ 1.0 × 10 -3 and minor allele frequency in controls ≥ 0.05 and (iv) when multiple SNPs were in strong LD (r 2 ≥ 0.80), only the most significant SNP with the lowest P add was selected. As a result, a total of 33 SNPs met the criteria (i), (ii) and (iii). Among them, we selected 16 SNPs according to the criteria (iv) for validation I, and the other 17 SNPs were in strong LD with the selected SNPs (Supplementary Table S3 , available at Carcinogenesis Online). The 16 SNPs were genotyped with the iPHEX Sequenom MassARRAY platform (Sequenom). The SNPs in validation I with P add < 0.05 and the same direction of associations as in the GWAS were further replicated in validation II by TaqMan assay (Applied Biosystems). Individuals who performed the genotyping were blinded to case or control status. Negative (water) control samples were included in each 384 well assay plate. In addition, about 10% of the samples were randomly selected to perform the repeated assays to control the quality of genotyping, and the results were 100% concordant.
Statistical analysis
We extracted the selected 24 042 SNPs from the imputed GWAS dataset and analyzed the associations between these SNPs and lung cancer susceptibility under an additive model in a logistic regression analysis by using PLINK 1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) (29) . Principal component analysis was conduced by EIGENSTRAT 3.0 software package (2,3). Then, we analyzed the results of two validation stages by SPSS version 12.0 (SPSS, Chicago). We further performed meta-analyses to combine the results of associated SNPs in two validation stages and in all three stages and tested for heterogeneity with MIX 2.0 software (http:// www.meta-analysis-made-easy.com/) (30) . We adjusted for four significant (P < 0.05) principal components revealed by principal component analysis, age, gender and pack-years of smoking in GWAS stage (2,3), while adjusted for age, gender and pack-years of smoking in validation stages. For the stratification analyses, we adjusted for age, gender and pack-year of smoking when appropriate. We evaluated both gene-environment interactions and gene-gene interactions by entering the multiplicative interaction terms into logistic regression models, with a 1 degree of freedom Wald test of the interaction terms. All statistical analyses were two sided. P < 2.0 × 10 -6 (calculated as ~0.05/24 042 SNPs) in the association analyses was considered pathway-based significant, whereas P < 5.0 × 10 -8 was considered genome-wide significant. 
Results
Identification of lung cancer susceptibility variants
Among the 24 042 SNPs of 798 genes selected from the imputed GWAS dataset, we selected 16 SNPs for validation I based on a stepwise series of criteria (as described in Materials and methods). As a result, two SNPs [rs2282987 in cyclin-dependent kinase 6 (CDK6) and rs2706748 in SH3 domain containing RING finger 1 (SH3RF1)] were well replicated with P add < 0.05 (Table I ) and thus entered last validation II; whereas other 14 SNPs were dropped from further consideration (Supplementary Table  S4 , available at Carcinogenesis Online). These two SNPs were also consistently well replicated in validation II with P add < 0.05 (Table I) . For combined association analyses, as the corresponding ORs were similar (all P het > 0.05), we used fixed model to combine the results of both validation stages and the results of all three stages (Table I) . When we combined the results of two validation stages, rs2282987 showed a significant association [OR = 1.13, 95% confidence interval (CI): 1.06-1.21, P add = 4.14 × 10
-4 ] after Bonferroni correction (P < 3.13 × 10 -3 , calculated as ~0.05/16), whereas rs2706748 showed a marginally significant association (OR = 1.12, 95% CI: 1.04-1.22, P add = 3.41 × 10 -3
). When we combined the results of all three stages, we found that the association for rs2282987 achieved genome-wide significance (OR = 1.18, 95% CI: 1.12-1.24, combined P add = 2.27 × 10 -9 ). Lung cancer risk was elevated with increasing copies of the variant rs2282987C allele. The subjects with rs2282987CC genotype had a higher lung cancer risk compared with subjects carrying rs2282987GG genotype at the pathway-based significance level (OR = 1.37, 95% CI: 1.21-1.55, combined P homo = 1.10 × 10 -6 ). Although rs2706748 did not show a significant association in the combined analyses of all three stages (OR = 1.17, 95% CI: 1.09-1.25, combined P add = 5.10 × 10 -6 ), its P add in each stage had reached the corresponding requirements (the P add in each of GWAS stage, validation I and validation II were 9.65 × 10 -5 , 3.26 × 10 -2 and 4.49 ×10 -2 , respectively), and thus this SNP was also included into the further analyses. The LD maps for all imputed SNPs on these two genes, CDK6 and SH3RF1, were shown in Figure 1 . A series of imputed SNPs were in high LD with the two associated SNPs; however, none of these SNPs reached the P values of the two associated SNPs. 
New variants, interactions and lung cancer risk
Stratification analyses
To evaluate the effects of genetic variants on lung cancer risk according to age, sex, smoking status and smoking history, we performed stratification analyses in the combined sample. Similarly, we examined the effects of two associated SNPs on histological subtypes (non-small cell lung cancer or small cell lung cancer), comparing each subgroup of cases against the entire group of controls (Table II) . The per-allele ORs for each SNP were similar in magnitude among age, sex, smoking status, smoking history and histological subgroups (all P het > 0.05). After stratification, the associations for rs2282987 were still significant in male (OR = 1.20, 95% CI: 1.13-1.28, P add = 2.06 × 10 -8 ) and smokers (OR = 1.24, 95% CI: 1.16-1.34, P add = 3.52 × 10 -9 ). For rs2706748, the association was persistently significant in male (OR = 1.22, 95% CI: 1.13-1.32, P add = 6.06 × 10 -7
). Of note, both SNPs showed significant associations with the risk of non-small cell lung cancer (for rs2282987: OR = 1.18, 95% CI: 1.12-1.25, P add = 3.07 × 10 -9
; for rs2706748: OR = 1.18, 95% CI: 1.11-1.26, P add = 1.11 × 10 -6 ), which accounted for ~92.1% of our cases (5892 of 6464).
Gene-environment and gene-gene interactions
We first performed gene-smoking status interaction analyses (Table III) . In the combined sample, the interaction terms of two SNPs with smoking status were not significant (all P interaction > 0.05). When we stratified the subjects according to age and gender, the interaction terms for rs2282987 and rs2706748 were significant in subjects aged 51-60 years (for rs2282987: OR interaction = 1.28, 95% CI: 1.06-1.55, P interaction = 1.04 × 10 -2 ; for rs2706748: OR interaction = 1.30, 95% CI: 1.03-1.65, P interaction = 3.03 × 10 -2 ), indicating that these two genetic variants interacted with smoking status to synergistically contribute to lung cancer risk in subjects aged 51-60 years. Then, we further evaluated the interactions of genetic variants with smoking history (Table III) . The two SNPs were not interacted with smoking history to contribute to lung cancer risk in the combined sample (all P interaction > 0.05). When we stratified the subjects according to age and gender, however, the interaction terms for rs2282987 and rs2706748 were also significant or marginally significant in subjects aged 51-60 years (for rs2282987: OR interaction = 1.15, 95% CI: 1.03-1.28, P interaction = 1.21 × 10 -2 ; for rs2706748: OR interaction = 1.15, 95% CI: 0.999-1.32, P interaction = 5.21 × 10 -2 ). We also tested the gene-gene interaction of these two associated SNPs (Table IV) . There was no interaction between rs2282987 and rs2706748 in the combined sample (P interaction > 0.05). We stratified the samples in terms of age, gender, smoking status and smoking history, and found that the interaction between rs2282987 and rs2706748 was significant in the subjects ≤50 years old (P interaction = 2.44 × 10 -2 ), male (P interaction = 1.57 × 10 -2 ), smokers (P interaction = 1.90 × 10 -2 ) and light smokers (P interaction = 4.56 × 10 -2 ).
Combined effects of genetic variants and smoking
We analyzed the combined effects of the two associated SNPs and smoking on lung cancer risk (Table V) . The non-smokers without any risk alleles (i.e. non-smokers carrying rs2282987GG and rs2706748TT genotypes) were considered as the reference group. We found that the OR in heavy smokers with the risk alleles of two associated SNPs (rs2282987GC+CC and rs2706748TC+CC) was ~1.43-fold higher than that in heavy smokers without any risk alleles, 2.22-fold higher than that in light smokers with the risk alleles of the two SNPs and 3.29-fold higher than that in non-smokers carrying the risk alleles of the two SNPs. Similarly, the OR in all smokers (light and heavy smokers) carrying the risk alleles of these two SNPs was ~1.46-fold higher than that in smokers without any risk alleles, and 2.33-fold higher than that in non-smokers carrying the risk alleles of the two SNPs. The risk alleles of these two SNPs had a limited effect on lung cancer risk in non-smokers.
Discussion
In our three-stage case-control study comprising a total of 6464 lung cancer cases and 7599 controls, we used imputation-based analyses to evaluate associations of a wide range of common genetic variants in the pathways of cell cycle regulation, apoptosis, oxidative stress and inflammation response with lung cancer susceptibility in Chinese populations. We identified a new lung cancer susceptibility variant (rs2282987 in CDK6 at 7q21.2) and a suggestive variant (rs2706748 in SH3RF1 at 4q32.3). Further gene-environment interaction analyses showed that rs2282987 and rs2706748 interacted with both smoking status and smoking history to contribute to lung cancer susceptibility in subjects aged 51-60 years.
rs2282987 is located in the intron of CDK6 at 7q21.2. CDK6 is a key regulator of cell cycle for G 1 phase progression and G 1 /S transition. Subtle alterations in the expression or activity of CDK6 could mediate cell cycle defects, resulting in unscheduled cell proliferation as well as genomic and chromosomal instability, and thus play a critical role in carcinogenesis (31) . Two previous studies have identified the associations of rs8 in CDK6 with the risk of medullary thyroid carcinoma (32) and non-serious ovarian cancer (33) in populations of European ancestry. However, this SNP is a rare SNP in Chinese populations and was not included in our study. Wang et al. (21) did not find significant association between genetic variation in CDK6 and lung cancer risk in populations of European ancestry, possibly because they only selected one potentially functional variant located in 3′-untranslated region of CDK6. Our study evaluated many common genetic variants in CDK6 and found rs2282987 was associated with lung cancer risk in Chinese populations. Given the important role of CDK6 in carcinogenesis and the significant association between genetic variations in CDK6 and lung cancer risk identified in our study, it is plausible that the genetic variations in CDK6 may confer susceptibility to lung cancer.
Although the association of rs2706748 was not significant in the combined analyses, the P add in each stage had consistently reached the corresponding requirements. rs2706748 is located in the intron of SH3RF1, also known as POSH (plenty of SH3 domains), at 4q32.3. SH3RF1 is a proapoptotic protein that can interact with activated Rac in response to apoptotic stimuli and enhance apoptosis by acting as a scaffold protein to link Rac to the downstream c-Jun N-terminal kinase pathway (34, 35) . Ectopic expression of SH3RF1 has been reported to lead to c-Jun N-terminal kinase activation (34, 35) , which would promote lung cancer development (36) . However, because the main effect of rs2704748 in the combined analyses was not significant in this study, the result should be treated cautiously and be further validated.
The gene-environment interaction analyses in our study showed that genetic variants interacted with smoking to contribute to lung cancer risk in subjects aged 51-60 years. Individuals at this special age may undergo major physiological changes, such as the alteration of sex hormone levels caused by climacterium and the decline of immune system function. Sex hormone may play an important role in lung cancer development, and may directly influence or modify the associations between smoking and lung cancer risk by interfering the metabolism of smoking-derived carcinogens (37) (38) (39) . Weakened immune system would make individuals more susceptible to the pathological changes caused by smoking. Furthermore, we evaluated the combined effects of smoking and two associated SNPs and found that smokers (particularly heavy smokers) with the risk alleles of rs2282987 and rs2706748 had the highest lung cancer risk. These findings strongly highlight the importance of discouraging smoking or reducing cigarette consumption in individuals with high-risk alleles to reduce lung cancer risk. Our study has several strengths and limitations. A major strength was that the initial imputation-based association analyses evaluated a wide range of common variants covering a wide range of genes, which facilitated comprehensive assessment of genetic factors in the selected lung cancer-related pathways that influence lung cancer risk. Moreover, as imputation errors must be considered in imputation-based association studies (5), we further genotyped the imputed SNPs in two validation populations to ensure that these associations were not due to imputation errors and reduce the probability of false-positives. In this study, however, we did not find associations with lung cancer risk for genetic variants in oxidative stress-related pathways or inflammation response-related pathways. One reason might be that some important oxidative stress-related or inflammation response-related genes, which had already been studied in previous GWAS studies (2, 3) were not included in this study. Another reason might be that we did not take SNPs with 1.0 × 10 -4 < P add ≤ 1.0 × 10 -2 into consideration. Moreover, because all the newly identified variants are intronic SNPs, future fine-mapping and functional studies are warranted to identify the causal variants and elucidate the biological mechanisms underlying the observed association of these SNPs with lung cancer risk. As the subjects in our study were all ethnic Han Chinese, the associations of these genetic variants with lung cancer risk need further validation in other ethnic populations.
In conclusion, we conducted imputation-based association analyses, following two-stage validations, to evaluate the associations of genetic variants in several canonical cancer-related pathways with lung cancer risk in Chinese populations. Our study has identified two new lung cancer susceptibility variants located in CDK6 and SH3RF1, further underscoring the etiology role of cell cycle regulation and apoptosis in lung cancer development. Furthermore, we identified that genetic variants may interact with smoking to affect lung cancer susceptibility in subjects aged 51-60 years; although the underlying mechanisms were not investigated in our study, our findings further highlight gene-environment interactions in lung cancer etiology. Finally, given smoking is the major risk factor for lung cancer development, understanding the combined effects of smoking and the risk variants of cancer-related pathways may help to identify high-risk individuals for the prevention of lung cancer in Chinese populations.
